Puget Technologies (OTCBB: PUGE) revealed today its new subsidiary, Cannabis BioTech is in negotiations with a leading international medical marijuana consultant to round out its research and development team.
Through his California based research firm, this prominent international authority designs and builds effective and efficient programs to assist dispensaries and medical cannabis companies to produce superior products.
Amid changing attitudes about marijuana, Cannabis Biotech is dedicated to developing medicinal cannabinoid delivery options using the latest scientific advances. The product development being conducted by Cannabis BioTech is expected to add to the growing body of data demonstrating marijuana’s medicinal benefits.
President and CEO of Puget Technologies Ron Leyland said, “We are very close to completing negotiations which will result in adding more strength to our scientific team and accelerating the development of our line of alternate delivery options.” He added, “The 1.7 Billion dollar U.S. medical marijuana market is expected to quadruple in size during the next five years, and having such expertise onboard will ensure our frontrunner position in the industry.”
More information about Cannabis BioTech can be found at http://www.cannabisbiotech.com.
About Puget Technologies (PUGE)
Puget Technologies is a publicly traded company on the OTCBB Market stock exchange under the ticker symbol PUGE. Headquartered in Ft. Lauderdale, Florida, Puget Technologies acquires, develops and sells leading edge consumer oriented products ready for rapid commercialization. Puget plans to become a recognized market leader in its product categories. Much of its resources are dedicated to research and development in order to provide consumers with quality options while meeting the expectations of its investors.
Safe Harbor Statement under the Private Securities Litigation Reform Act of 1995: This news release contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange act of 1934, as amended, including statements that include the words "believes," "expects," "anticipates," or similar expressions. Such forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause the actual results, performance or achievements of the company to differ materially from those expressed or implied by such forward looking statements. In addition, description of anyone's past success, either financial or strategic, is no guarantee of future success. This news release only speaks as of the date of its distribution.
|SKTO Announces Acquisition of Accomplished Medical Cannabis Consulting Firm ()|
|Puget Technologies Signs Contract with International Cannabis Authority (2013/10/10)|
|Puget Technologies Establishes Cannabis BioTech (2013/9/23)|
|Medical Cannabis Financial Group, Inc. Announces Merger Transaction With Refill Energy, Inc. (2013/8/7)|
|Cheryl Shuman, Medical Cannabis Industry Icon & Brand Ambassador for Medical Marijuana Inc.'s HempMedsPX, Defends Medical Cannabis Use on Dr. Phil This Friday, October 25th (2013/10/23)|
|Medical Marijuana Inc.'s HempMedsPX Named Sponsor of High Times Medical Cannabis Cup in Seattle, Washington (2013/8/28)|
|BBC World News Features Legal Industrial Hemp-Based Cannabidiol (CBD) Product With Cheryl Shuman, Medical Marijuana Inc.'s HempMedsPX Brand Ambassador & Medical Cannabis Advocate, on Friday, October 25th (2013/10/25)|
|Medical Cannabis Payment Solutions Announces Ghost -- The Only Mobile App Platform for Medical Marijuana Dispensaries (2013/9/24)|
|Medical Cannabis Payment Solutions CEO to Appear on Radio Program, Discuss Solutions (2013/9/26)|
|Medical Cannabis Payment Solutions to Attend National Business Conference (2013/10/1)|
|Start Premium Trial||Register For Free|
|P||F||Fund Financial Data (13,000+ funds)|
|P||F||Stock Financial Data (7,000+ stocks)|
|P||F||Stock and Fund Screeners (basic)|
|P||F||Investing Articles and Market Commentary|
|P||F||Articles Archive (>30 days)|
|P||F||Discuss (dozens of stock, fund, bond, and general bulletin boards)|
|P||F||Portfolio Manager (basic)|
|P||F||Morningstar Investment Classroom|
|P||F||Access Your Portfolio Anytime, Anywhere via Your Mobile Device|
|P||Morningstar Fund Analyst Reports (full research on 1,700 funds, ETFs, and CEFs)|
|P||Morningstar Stock Analyst Reports (full research on more than 1,100 stocks)|
|P||Portfolio Manager (advanced with 10 X-Ray analyses, including recommendations)|
|P||Portfolio Monitor (monthly and on-demand personalized portfolio statements)|
|P||Morningstar Proprietary Stock Information (stock star ratings, buy/sell prices, economic moat ratings, and more)|
|P||Morningstar 5-Star Stock and Fund Favorites & Red Flags eNewsletters|
|P||Premium Stock and Fund Screeners (advanced with nearly infinite ways to find the best securities for you)|
|P||Discounts on Morningstar newsletters, books, seminars, and more|
Access these features and more when you sign up for Free Membership.
Join Morningstar today. It's Free.
Access these features and more when you sign up for Premium Membership.
Start your free 14-day trial today online
Your subscription may be tax deductible. Please contact your tax advisor.